+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Anti-Obesity Drugs Market by Drug Type, Mechanism of Action - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5317899
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Anti-Obesity Drugs Market grew from USD 3.83 billion in 2023 to USD 4.09 billion in 2024. It is expected to continue growing at a CAGR of 6.86%, reaching USD 6.10 billion by 2030.

Anti-obesity drugs encompass pharmaceutical compounds used to treat obesity by altering fundamental processes of the body's regulation of weight. The scope of these drugs includes appetite suppression, metabolic enhancement, and fat absorption inhibition, and they are critical in addressing obesity, a growing global health concern linked to several chronic diseases. The necessity for anti-obesity drugs stems from the alarming rise in obesity rates worldwide, which significantly strains healthcare systems and elevates the risk of diabetes, cardiovascular diseases, and certain cancers. Applications are primarily clinical and are prescribed alongside lifestyle modifications, targeting individuals with a body mass index (BMI) over 30, or those with a BMI over 27 with additional risk factors. End-use includes hospitals, clinics, and homecare settings, underscored by an increase in self-medicated weight management solutions.

Demand is driven by increased awareness of health and wellness, advancements in drug formulations, and a favorable regulatory landscape. However, growth challenges persist, including high R&D costs, potential side effects, stringent regulatory requirements, and societal stigma around weight loss medication. Opportunities exist in personalized medicine, leveraging genetic information to design tailor-made therapeutic solutions, and digital health integration for remote monitoring and adherence. Companies can explore non-traditional approaches, such as incorporating artificial intelligence for predictive analytics to refine patient eligibility and treatment outcomes. The market also faces limitations due to competition from non-pharmaceutical weight management methods, including nutritional and surgical interventions.

Innovation should focus on minimizing side effects, enhancing efficacy, and developing multi-action formulations. Partnerships between pharmaceuticals and technology firms could lead to breakthroughs in patient engagement platforms. Overall, while the market for anti-obesity drugs is promising, it requires addressing inherent limitations by prioritizing safety, efficacy, and accessibility to ensure broad acceptance and sustained growth.

Understanding Market Dynamics in the Anti-Obesity Drugs Market

The Anti-Obesity Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising burden of obesity and related chronic diseases
    • Rapid consumption of unhealthy fast-foods and ready meals
    • Increasing inclination towards health & fitness
  • Market Restraints
    • Side-effects associated with drugs
  • Market Opportunities
    • Growing awareness among people with collaborative strategies
    • Recent advancements in drug treatment of obesity
  • Market Challenges
    • Availability of alternative treatment options in market

Exploring Porter’s Five Forces for the Anti-Obesity Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Anti-Obesity Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Anti-Obesity Drugs Market

External macro-environmental factors deeply influence the performance of the Anti-Obesity Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Anti-Obesity Drugs Market

The Anti-Obesity Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Anti-Obesity Drugs Market

The Anti-Obesity Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Anti-Obesity Drugs Market

The Anti-Obesity Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Obesity Drugs Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co. Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus Inc..

Market Segmentation & Coverage

This research report categorizes the Anti-Obesity Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Type
    • Over-The-Counter Drugs
    • Prescription Drugs
  • Mechanism of Action
    • Centrally Acting Drugs
    • Peripherally Acting Drugs
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising burden of obesity and related chronic diseases
5.1.1.2. Rapid consumption of unhealthy fast-foods and ready meals
5.1.1.3. Increasing inclination towards health & fitness
5.1.2. Restraints
5.1.2.1. Side-effects associated with drugs
5.1.3. Opportunities
5.1.3.1. Growing awareness among people with collaborative strategies
5.1.3.2. Recent advancements in drug treatment of obesity
5.1.4. Challenges
5.1.4.1. Availability of alternative treatment options in market
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Anti-Obesity Drugs Market, by Drug Type
6.1. Introduction
6.2. Over-The-Counter Drugs
6.3. Prescription Drugs
7. Anti-Obesity Drugs Market, by Mechanism of Action
7.1. Introduction
7.2. Centrally Acting Drugs
7.3. Peripherally Acting Drugs
8. Americas Anti-Obesity Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Anti-Obesity Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Anti-Obesity Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANTI-OBESITY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTI-OBESITY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTI-OBESITY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTI-OBESITY DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CENTRALLY ACTING DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 16. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 17. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 18. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 19. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 20. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 21. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 22. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 23. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 27. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 28. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 29. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 31. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 32. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 33. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 34. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 35. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 36. INDONESIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 37. INDONESIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 38. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 40. MALAYSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 41. MALAYSIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 42. PHILIPPINES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. PHILIPPINES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 44. SINGAPORE ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. SINGAPORE ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 46. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 47. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 48. TAIWAN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. TAIWAN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 50. THAILAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 51. THAILAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 52. VIETNAM ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 53. VIETNAM ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 59. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 61. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 62. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 63. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 64. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 65. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 67. ISRAEL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 68. ISRAEL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 69. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 70. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 71. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 73. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 74. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 75. NORWAY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. NORWAY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 77. POLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 78. POLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 79. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 83. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 87. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 88. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 89. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 90. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 91. SWITZERLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. SWITZERLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 93. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 94. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 100. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Anti-Obesity Drugs Market, which are profiled in this report, include:
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Currax Pharmaceuticals LLC
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Norgine BV
  • Novo Nordisk AS
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • SHIONOGI & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vivus Inc.

Methodology

Loading
LOADING...

Table Information